Bristol-Myers Squibb Company

Symbol: BRM.DE

XETRA

49.65

EUR

Market price today

  • 11.0847

    P/E Ratio

  • 0.2881

    PEG Ratio

  • 103.72B

    MRK Cap

  • 0.01%

    DIV Yield

Bristol-Myers Squibb Company (BRM-DE) Stock Price & Analysis

Shares Outstanding

2089.1M

Gross Profit Margin

0.76%

Operating Profit Margin

0.21%

Net Profit Margin

0.18%

Return on Assets

0.08%

Return on Equity

0.26%

Return on Capital Employed

0.13%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Dr. Giovanni Caforio M.D.
Full-time employees:34300
City:New York
Address:430 East 29th Street
IPO:1999-05-14
CIK:

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

General Outlook

In simple terms, Bristol-Myers Squibb Company has 2089.1 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.762% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.209%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.178%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.084% return, is a testament to Bristol-Myers Squibb Company's adeptness in optimizing resource deployment. Bristol-Myers Squibb Company's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.263%. Furthermore, the proficiency of Bristol-Myers Squibb Company in capital utilization is underscored by a remarkable 0.129% return on capital employed.

Stock Prices

Bristol-Myers Squibb Company's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $47.2, while its low point bottomed out at $46.6. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Bristol-Myers Squibb Company's stock market.

Liquidity Ratios

Analyzing BRM.DE liquidity ratios reveals its financial health of the firm. The current ratio of 142.71% gauges short-term asset coverage for liabilities. The quick ratio (123.73%) assesses immediate liquidity, while the cash ratio (51.50%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio142.71%
Quick Ratio123.73%
Cash Ratio51.50%

Profitability Ratios

BRM.DE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 18.75% underscores its earnings before tax deductions. The effective tax rate stands at 4.74%, revealing its tax efficiency. The net income per EBT, 95.08%, and the EBT per EBIT, 89.63%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 20.92%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin18.75%
Effective Tax Rate4.74%
Net Income per EBT95.08%
EBT per EBIT89.63%
EBIT per Revenue20.92%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.43, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 294.85% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding124
Days of Inventory Outstanding91
Operating Cycle214.66
Days of Payables Outstanding111
Cash Conversion Cycle103
Receivables Turnover2.95
Payables Turnover3.28
Inventory Turnover4.02
Fixed Asset Turnover5.60
Asset Turnover0.47

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 6.82, and free cash flow per share, 6.23, depict cash generation on a per-share basis. The cash per share value, 6.04, showcases liquidity position. A payout ratio of 0.59 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.31, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share6.82
Free Cash Flow per Share6.23
Cash per Share6.04
Payout Ratio0.59
Operating Cash Flow Sales Ratio0.31
Free Cash Flow to Operating Cash Flow Ratio0.91
Cash Flow Coverage Ratio0.33
Short Term Coverage Ratio4.22
Capital Expenditure Coverage Ratio11.46
Dividend Paid and Capex Coverage Ratio2.33
Dividend Payout Ratio0.04

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 43.57%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.41, we discern the balance between debt and equity financing. The long-term debt to capitalization, 56.47%, and total debt to capitalization, 58.49%, ratios shed light on its capital structure. An interest coverage of 8.08 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio43.57%
Debt Equity Ratio1.41
Long Term Debt to Capitalization56.47%
Total Debt to Capitalization58.49%
Interest Coverage8.08
Cash Flow to Debt Ratio0.33
Company Equity Multiplier3.23

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 21.75, provides a glimpse into top-line earnings distributed across each share. Net income per share, 3.88, reflects the portion of profit attributed to each share. The book value per share, 14.22, represents the net asset value distributed per share, while the tangible book value per share, -9.26, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share21.75
Net Income Per Share3.88
Book Value Per Share14.22
Tangible Book Value Per Share-9.26
Shareholders Equity Per Share14.22
Interest Debt Per Share20.60
Capex Per Share-0.58

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -2.50%, indicates top-line expansion, while the gross profit growth, -4.74%, reveals profitability trends. EBIT growth, -8.82%, and operating income growth, -8.82%, offer insights into operational profitability progression. The net income growth, 26.84%, showcases bottom-line expansion, and the EPS growth, 30.64%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-2.50%
Gross Profit Growth-4.74%
EBIT Growth-8.82%
Operating Income Growth-8.82%
Net Income Growth26.84%
EPS Growth30.64%
EPS Diluted Growth30.85%
Weighted Average Shares Growth-2.86%
Weighted Average Shares Diluted Growth-3.59%
Dividends per Share Growth5.39%
Operating Cash Flow Growth6.08%
Free Cash Flow Growth5.88%
10-Year Revenue Growth per Share118.26%
5-Year Revenue Growth per Share57.45%
3-Year Revenue Growth per Share15.52%
10-Year Operating CF Growth per Share210.66%
5-Year Operating CF Growth per Share84.16%
3-Year Operating CF Growth per Share7.64%
10-Year Net Income Growth per Share148.79%
5-Year Net Income Growth per Share27.91%
3-Year Net Income Growth per Share197.37%
10-Year Shareholders Equity Growth per Share54.31%
5-Year Shareholders Equity Growth per Share65.55%
3-Year Shareholders Equity Growth per Share-15.08%
10-Year Dividend per Share Growth per Share63.25%
5-Year Dividend per Share Growth per Share43.29%
3-Year Dividend per Share Growth per Share27.05%
Receivables Growth9.52%
Inventory Growth13.81%
Asset Growth-1.72%
Book Value per Share Growth-2.46%
Debt Growth1.83%
R&D Expense Growth-2.21%
SGA Expenses Growth-0.54%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 136,183,397,280, captures the company's total value, considering both debt and equity. Income quality, 1.72, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.14, gauges operational efficiency, while the research and development to revenue, 20.66%, highlights investment in innovation. The ratio of intangibles to total assets, 51.13%, indicates the value of non-physical assets, and capex to operating cash flow, -8.72%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value136,183,397,280
Income Quality1.72
Sales General and Administrative to Revenue0.14
Research and Development to Revenue20.66%
Intangibles to Total Assets51.13%
Capex to Operating Cash Flow-8.72%
Capex to Revenue-2.69%
Capex to Depreciation-12.39%
Stock-Based Compensation to Revenue1.15%
Graham Number35.23
Return on Tangible Assets17.26%
Graham Net Net-19.63
Working Capital9,508,000,000
Tangible Asset Value-19,169,000,000
Net Current Asset Value-33,904,000,000
Invested Capital1
Average Receivables14,600,500,000
Average Payables3,149,500,000
Average Inventory2,500,500,000
Days Sales Outstanding124
Days Payables Outstanding111
Days of Inventory On Hand91
ROIC12.65%
ROE0.27%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.02, and the price to book ratio, 3.02, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.03, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 7.23, and price to operating cash flows, 6.42, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.02
Price to Book Ratio3.02
Price to Sales Ratio2.03
Price Cash Flow Ratio6.42
Price Earnings to Growth Ratio0.29
Enterprise Value Multiple3.26
Price Fair Value3.02
Price to Operating Cash Flow Ratio6.42
Price to Free Cash Flows Ratio7.23
Price to Tangible Book Ratio3.61
Enterprise Value to Sales3.03
Enterprise Value Over EBITDA7.10
EV to Operating Cash Flow9.83
Earnings Yield7.56%
Free Cash Flow Yield11.91%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Bristol-Myers Squibb Company (BRM.DE) on the XETRA in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 11.085 in 2024.

What is the ticker symbol of Bristol-Myers Squibb Company stock?

The ticker symbol of Bristol-Myers Squibb Company stock is BRM.DE.

What is company IPO date?

IPO date of Bristol-Myers Squibb Company is 1999-05-14.

What is company current share price?

Current share price is 49.650 EUR.

What is stock market cap today?

The market cap of stock today is 103723816589.000.

What is PEG ratio in 2024?

The current 0.288 is 0.288 in 2024.

What is the number of employees in 2024?

In 2024 the company has 34300.